The World Health Organization warns of rapid spread of chikungunya from Indian Ocean islands into Africa, Asia and Europe that could soon affect billions of people. This follows the major surges of cases in La reunion, Mayotte and Mauritius earlier this year. WHO observes similar warning signs as in the last major outbreak 2 decades ago that affected half a million people worldwide.
The current epidemiological situation calls for increase disease surveillance and preparedness in regions where suitable vector of chikungunya is present.
Optimal mosquito protection 24/7 also in cities and urban settings to also protect against others mosquito-borne diseases such as dengue.
Vaccination: Two vaccines, a live-attenuated vaccine (Ixchiq®) and a virus-like particle vaccine (Vimkunya®) are authorized in the U.S. (FDA) and Europe (EMA) but not yet licensed in Switzerland (Swissmedic). However, the use of the Ixchiq® in elderly is currently under scrutiny.
- In May 2025, the vaccine was temporarily contraindicated in people 65 and older by the French National Authority for Health (HAS) and recently reauthorized (see EMA) because this is the age group in which the disease can be severe. However, EMA emphasizes that Ixchiq© should only be used when there is a significant risk of chikungunya infection and after a careful benefit-risk evaluation in all age groups. (see also previous ECTM 16.06.2025).
- In the U.S., the health authorities limited its use in people 60 and older and the restriction is still active (see CDC).